EP1474125A1 - The use of omega-3 polyunsaturated acids ethyl esters in patients suffering from heart failure - Google Patents

The use of omega-3 polyunsaturated acids ethyl esters in patients suffering from heart failure

Info

Publication number
EP1474125A1
EP1474125A1 EP03739455A EP03739455A EP1474125A1 EP 1474125 A1 EP1474125 A1 EP 1474125A1 EP 03739455 A EP03739455 A EP 03739455A EP 03739455 A EP03739455 A EP 03739455A EP 1474125 A1 EP1474125 A1 EP 1474125A1
Authority
EP
European Patent Office
Prior art keywords
epa
heart failure
ethyl esters
patients suffering
medicament
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP03739455A
Other languages
German (de)
French (fr)
Inventor
Jadranka Rogan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Victorix Assets Ltd
Original Assignee
Victorix Assets Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Victorix Assets Ltd filed Critical Victorix Assets Ltd
Publication of EP1474125A1 publication Critical patent/EP1474125A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Definitions

  • the present invention relates to the use of ethyl esters of polyunsaturated acids in the ⁇ -3 series obtained from fish oil, and in particular eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) ethyl esters at high concentrations, alone or mixed, to prepare pharmaceutical compositions useful in reducing the risk of mortality, caused by sudden death, in patients suffering from heart failure.
  • EPA eicosapentaenoic acid
  • DHA docosahexaenoic acid
  • Heart failure is a clinical symptom caused by the inability of the heart to pump a quantity of blood sufficient for venous return and metabolic needs, leading to congestion of the pulmonary and systemic circulation.
  • the polyunsaturated fatty acids in the ⁇ -3 series in particular EPA and DHA, are known for their potential usefulness in the treatment of cardiovascular diseases and their risk factors.
  • EP 0,409,903-Bl, patent IT 1,235,978 and others disclose their efficacy in the treatment of hyperlipaemia, hypercholesterolaemia and hypertension.
  • the usefulness of this treatment is independent of the etiopathogenesis of the heart failure, and in particular of the presence or absence of a prior ischaemic coronary event.
  • heart failure was experimentally induced in dogs by injecting latex microspheres at coronary level to induce a malfunction of the left ventricle, which was evaluated in terms of reduction in the ejection fraction accompanied by dilatation and hypertrophy of the ventricle, reduction in cardiac output and other characteristic signs of heart failure in man.
  • One group of animals was then treated orally with one 0.5/1 g capsule of EPA and DHA ethyl esters a day for 8 weeks, and a second comparison group was treated with placebo capsules. Any mortality which occurred during that period was recorded. The survival rate was significantly higher in the treated group than the placebo group.
  • the experimental model proved to be applicable both to healthy animals and to those which had suffered prior experimentally induced heart attacks.
  • compositions of ⁇ -3 polyunsaturated acids ethyl esters of the invention mainly represented by EPA and/or DHA ethyl esters at a high concentration, can easily be obtained by procedures well known to experts in the art, such as those described in WO 89/11521, US 5130061, IT 1,235,879, US 4,377,526, US 4,554,107 and others, which are incorporated herein as regards the production processes.
  • the content of EPA and/or DHA ethyl esters generally exceeds 25%; in particular it ranges between approx. 50% and approx. 100%, and preferably between 80% and 90% (approx. 85%).
  • the percentage of EPA ethyl ester is preferably 40 to 60%, and the percentage of DHA ethyl ester is preferably in the 25-50% range; in any event the ratio between the EPA and DHA ethyl esters should be between 0.9 and 1.5.
  • said oily compositions comprising high concentrations of EPA and/or DHA ethyl esters are used to make a medicament useful in reducing the risk of mortality caused by sudden death in patients suffering from heart failure.
  • the medicament is preferably administered orally, in particular using a pharmaceutical formulation of soft gelatin capsules.
  • the preparation process of said capsules, which are particularly suitable to carry oily active ingredients, is well known to those skilled in the art.
  • the unit dose of the capsules is usually 0.5-1 g, and preferably 1 g, while the daily dose is between 0.5 and 2 g, depending on the severity of the disorder and the physician's opinion, and preferably around 1 g/day.
  • oral formulations may also be suitable, such as hard capsules, tablets and granulates in which the oily composition can be adsorbed on a solid medium, or drops, syrups, etc., as known in pharmaceutical technology.
  • Other pharmaceutical forms include parenteral formulations such as sterile emulsions and the like.
  • the medicament according to the invention may also include other active ingredients with synergistic or complementary activity; as well as diluents, thickeners, surfactants, dyes, flavouring agents, stabilisers and antioxidants, according to the usual practice.
  • Particularly preferred antioxidants are vitamin E (tocopherol) and p-oxybenzoates.
  • the model used is the one described by H.N. Sabbat et al. (Am. J. Physiol., 260, 1379, 1991) in which the incidence, frequency and complexity of the spontaneous or inducible tachyarrhythmias agrees with the observations made in patients suffering from heart failure.
  • heart failure was induced by coronary microembolisations with latex microspheres, repeated until a loss of contractile myocardium was angiographically recorded, this being defined as a left ventricle ejection fraction equal to or less than 35%.
  • composition of soft gelatin capsules containing 1 g of a mixture of EPA and DHA ethyl esters with a titre of approx. 85%
  • composition of soft gelatm capsules containing 1 g of a mixture of EPA and DHA ethyl esters with a titre of approx. 85%

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

The invention discloses the use of ethyl esters of polyunsaturated acids in the ω-3 series obtained from fish oil, and in particular eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) ethyl esters at high concentrations, alone or mixed, to prepare pharmaceutical compositions useful in reducing the risk of sudden death, in patients suffering from heart failure.

Description

THE USE OF OMEGA-3 POLYUNSATURATED ACIDS ETHYL ESTERS IN PATIENTS SUFFERING FROM HEART FAILURE
The present invention relates to the use of ethyl esters of polyunsaturated acids in the ω-3 series obtained from fish oil, and in particular eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) ethyl esters at high concentrations, alone or mixed, to prepare pharmaceutical compositions useful in reducing the risk of mortality, caused by sudden death, in patients suffering from heart failure.
BASIS OF THE INVENTION
Heart failure is a clinical symptom caused by the inability of the heart to pump a quantity of blood sufficient for venous return and metabolic needs, leading to congestion of the pulmonary and systemic circulation.
Despite the progress made with pharmacological treatment, which now includes angiotensin-converting enzyme inhibitors (ACE) and beta-blockers in addition to the cardioactive glycosides and diuretics that have long been in use, mortality in patients with heart failure remains high, ranging between 7 and 11% per annum (S.G. Priori et al., European Heart Journal, 22, 1374, 2001). These mortality figures are independent of the original causes of heart failure such as ischaemic events, dilated cardiomyopathy, and the like. Sudden cardiac death accounts for 60% of deaths.
Current treatments are therefore insufficient to prevent mortality in patients suffering from heart failure. In particular, none of the drugs generally used, with the possible exception of beta-blockers, whose use is limited by their serious contraindications, has demonstrated specific preventive efficacy against the risk of sudden death.
The polyunsaturated fatty acids in the ω-3 series, in particular EPA and DHA, are known for their potential usefulness in the treatment of cardiovascular diseases and their risk factors.
By way of example, EP 0,409,903-Bl, patent IT 1,235,978 and others disclose their efficacy in the treatment of hyperlipaemia, hypercholesterolaemia and hypertension.
A clinical trial conducted with formulations containing a high concentration of EPA and DHA ethyl esters on patients who had suffered prior myocardial infarctions demonstrated their efficacy in reducing mortality, and especially sudden death (Lancet, 354, 4476, 1999).
However, patients with manifest heart failure were excluded from that trial.
Patients with manifest heart failure were also excluded from other trials in which the administration of ω-3 polyunsaturated acid analogues to post-infarction patients by various procedures (diets and diet supplements) led to reductions in mortality or morbidity (Lancet ii, 257, 1989; Circulation, 99, 779, 1999; Cardiovascular Drugs and Therapy, 11, 485, 1997).
Even now, the literature regarding these polyunsaturated fatty acids, especially EPA and DHA esters, does not describe or suggest their use to reduce mortality in patients suffering from heart failure.
SUMMARY OF THE INVENTION
It has now been found that EPA and DHA ethyl esters can be used to reduce mortality caused by sudden death in patients suffering from heart failure.
The usefulness of this treatment, as clearly exemplified by the pharmacological data, is independent of the etiopathogenesis of the heart failure, and in particular of the presence or absence of a prior ischaemic coronary event.
DESCRIPTION OF THE INVENTION
The treatment method has been tested and verified, for ethical reasons, on animal models reported in the literature and adapted for the particular use required. Briefly, heart failure was experimentally induced in dogs by injecting latex microspheres at coronary level to induce a malfunction of the left ventricle, which was evaluated in terms of reduction in the ejection fraction accompanied by dilatation and hypertrophy of the ventricle, reduction in cardiac output and other characteristic signs of heart failure in man. One group of animals was then treated orally with one 0.5/1 g capsule of EPA and DHA ethyl esters a day for 8 weeks, and a second comparison group was treated with placebo capsules. Any mortality which occurred during that period was recorded. The survival rate was significantly higher in the treated group than the placebo group. The experimental model proved to be applicable both to healthy animals and to those which had suffered prior experimentally induced heart attacks.
The compositions of ω-3 polyunsaturated acids ethyl esters of the invention, mainly represented by EPA and/or DHA ethyl esters at a high concentration, can easily be obtained by procedures well known to experts in the art, such as those described in WO 89/11521, US 5130061, IT 1,235,879, US 4,377,526, US 4,554,107 and others, which are incorporated herein as regards the production processes.
The content of EPA and/or DHA ethyl esters generally exceeds 25%; in particular it ranges between approx. 50% and approx. 100%, and preferably between 80% and 90% (approx. 85%). In the ambit of these EPA and DHA concentrations in a mixture, the percentage of EPA ethyl ester is preferably 40 to 60%, and the percentage of DHA ethyl ester is preferably in the 25-50% range; in any event the ratio between the EPA and DHA ethyl esters should be between 0.9 and 1.5.
According to the invention, said oily compositions comprising high concentrations of EPA and/or DHA ethyl esters are used to make a medicament useful in reducing the risk of mortality caused by sudden death in patients suffering from heart failure. For this clinical use, in accordance with the experimental findings, the medicament is preferably administered orally, in particular using a pharmaceutical formulation of soft gelatin capsules. The preparation process of said capsules, which are particularly suitable to carry oily active ingredients, is well known to those skilled in the art. The unit dose of the capsules is usually 0.5-1 g, and preferably 1 g, while the daily dose is between 0.5 and 2 g, depending on the severity of the disorder and the physician's opinion, and preferably around 1 g/day.
Other oral formulations may also be suitable, such as hard capsules, tablets and granulates in which the oily composition can be adsorbed on a solid medium, or drops, syrups, etc., as known in pharmaceutical technology. Other pharmaceutical forms include parenteral formulations such as sterile emulsions and the like.
The medicament according to the invention may also include other active ingredients with synergistic or complementary activity; as well as diluents, thickeners, surfactants, dyes, flavouring agents, stabilisers and antioxidants, according to the usual practice. Particularly preferred antioxidants are vitamin E (tocopherol) and p-oxybenzoates.
Typical pharmacological results of the therapeutic activity claimed are reported in Examples 1 and 2, and some compositions of soft gelatin capsule formulations are reported in Examples 3-6.
Example 1
Efficacy of EPA and DHA ethyl esters in dogs with heart failure following myocardial ischaemia
The effect of EPA and DHA ethyl esters in heart failure has been studied in a canine model developed by Adamson and Vanoli (Journal of the American College of Cardiology, 37, 1741, 2001). Myocardial infarction was induced in mongrel dogs weighing between 20 and 35 kg by lengthy occlusion (20 min) of the left descending coronary artery during thoracotomy under general anaesthesia. In the animals in which transient ischaemia and physical exercise induced ventricular fibrillation after a suitable recovery period, heart failure was induced by injecting latex microspheres into the circumflex coronary artery, and the injections were repeated until a left ventricle ejection fraction of approx. 35% was recorded.
According to the findings reported in the above-mentioned study, these left ventricular malfunction conditions caused sudden death of all the animals within eight weeks; however, daily treatment of 10 animals with a capsule containing 0.5 g of EPA and DHA ethyl esters with a titre of 85%, as described in Example 5, kept 7 animals alive during the same period.
These results demonstrate that the compounds of the invention protect 70% of animals with heart failure consequent on myocardial ischaemia against sudden death.
Example 2
Efficacy of EPA and DHA ethyl esters in dogs with heart failure in the absence of prior ischaemic events
The effect of EPA and DHA ethyl esters has also been studied in an experimental model in mongrel dogs in which chronic malfunction of the left ventricle was induced in the absence of a prior myocardial infarction.
The model used is the one described by H.N. Sabbat et al. (Am. J. Physiol., 260, 1379, 1991) in which the incidence, frequency and complexity of the spontaneous or inducible tachyarrhythmias agrees with the observations made in patients suffering from heart failure. Once again, heart failure was induced by coronary microembolisations with latex microspheres, repeated until a loss of contractile myocardium was angiographically recorded, this being defined as a left ventricle ejection fraction equal to or less than 35%.
Eighteen dogs which survived the operation in acceptable conditions were divided into two groups and treated daily for eight weeks with capsules containing 1 g of EPA and DHA ethyl esters with a titre of 85%, as described in Example 3, or with placebo capsules (olive oil). The programmed ventricular stimulation induced sustained ventricular tachycardia or ventricular fibrillation in seven of the nine dogs in the placebo group, which was terminated in all cases by direct-current cardioversion. In the group treated with the active ingredients, the electrophysiological test only induced ventricular fibrillation in two out of nine dogs.
These results demonstrate that even in the absence of prior myocardial ischaemia, EPA and DHA ethyl esters protect over 70% of animals with experimental heart failure against malignant tachyarrhythmias which would lead to sudden cardiac death in the absence of suitable defibrillation.
Example 3
Composition of soft gelatin capsules containing 1 g of a mixture of EPA and DHA ethyl esters with a titre of approx. 85%
EPA ethyl ester 525 mg
DHA ethyl ester 315 mg d-alpha tocopherol 4 IU gelatin 246 mg glycerol 118 mg red iron oxide 2.27 mg yellow iron oxide 1.27 mg Example 4
Composition of soft gelatm capsules containing 1 g of a mixture of EPA and DHA ethyl esters with a titre of approx. 85%
Polyunsaturated fatty acids ethyl esters 1000 mg with an EPA ethyl ester and DHA ethyl ester content of 850 mg d-l-α tocopherol 0.3 mg gelatin succinate 233 mg glycerol 67 mg sodium p-oxybenzoate 1.09 mg sodium propyl p-oxybenzoate 0.54 mg Example 5
Composition of soft gelatin capsules containing 0.5 g of EPA and DHA ethyl esters with a titre of approx. 85%
Polyunsaturated fatty acids ethyl esters 500 mg with EPA ethyl ester and DHA ethyl ester content,
0.9-1.5 ratio, of 425 mg d-l-α tocopherol 0.15 mg gelatin succinate 139 mg glycerol 40 mg sodium ethyl p-oxybenzoate 0.66 mg sodium propyl p-hydroxybenzoate 0.32 mg
Example 6
Composition of soft gelatin capsules containing 0.5 g of polyunsaturated fatty acids ethyl esters
DHA ethyl ester > 400 mg d-l-α tocopherol 0.15 mg gelatin succinate 139 mg glycerol 40 mg sodium ethyl p-oxybenzoate 0.66 mg sodium propyl p-hydroxybenzoate 0.32 mg

Claims

1. Use of a composition of EPA and DHA ethyl esters for the preparation of a medicament useful in reducing mortality caused by "sudden death" in patients suffering from heart failure, wherein the EPA and DHA ethyl ester content exceeds 25%.
2. Use as claimed in claim 1, wherein the medicament is useful in reducing mortality in patients suffering from heart failure of any origin.
3. Use as claimed in claims 1-2, wherein the medicament is useful in reducing mortality in patients suffering from heart failure caused by dilated cardiomyopathy.
4. Use as claimed in claims 1-3, wherein the medicament is useful in reducing mortality in patients suffering from heart failure caused by ischaemic events.
5. Use as claimed in claims 1-4, wherein the EPA and DHA ethyl ester content is between 50 and 100%.
6. Use as claimed in claims 1-5, wherein the EPA and DHA ethyl ester content is between 80 and 90%.
7. Use as claimed in claims 1-6, wherein the medicament is administered orally.
8. Use as claimed in claims 1-7, wherein the medicament is used in soft gelatin capsules.
9. Use as claimed in claims 7 and 8, wherein the medicament is used at the dose of 0.5 - 2 g a day.
10. Use as claimed in claims 7-9, wherein the medicament is used at the dose of 1 g a day.
11. Use as claimed in claims 1-10, wherein the EPA ethyl ester content is between 40 and 60% and the DHA ethyl ester content is between 25 and 50%.
12. Use as claimed in claims 1-10, wherein the ratio of EPA to DHA ethyl ester contents is between 0.9 and 1.5.
EP03739455A 2002-02-12 2003-02-05 The use of omega-3 polyunsaturated acids ethyl esters in patients suffering from heart failure Withdrawn EP1474125A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IT2002MI000269A ITMI20020269A1 (en) 2002-02-12 2002-02-12 USE OF OMEGA-3 POLYUNSATURATED ACID ETHYL STERES IN PATIENTS WITH HEART INSUFFICIENCY
ITMI20020269 2002-12-19
PCT/EP2003/001108 WO2003068216A1 (en) 2002-02-12 2003-02-05 The use of omega-3 polyunsaturated acids ethyl esters in patients suffering from heart failure

Publications (1)

Publication Number Publication Date
EP1474125A1 true EP1474125A1 (en) 2004-11-10

Family

ID=11449201

Family Applications (1)

Application Number Title Priority Date Filing Date
EP03739455A Withdrawn EP1474125A1 (en) 2002-02-12 2003-02-05 The use of omega-3 polyunsaturated acids ethyl esters in patients suffering from heart failure

Country Status (4)

Country Link
EP (1) EP1474125A1 (en)
AU (1) AU2003210210A1 (en)
IT (1) ITMI20020269A1 (en)
WO (1) WO2003068216A1 (en)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9901809D0 (en) 1999-01-27 1999-03-17 Scarista Limited Highly purified ethgyl epa and other epa derivatives for psychiatric and neurological disorderes
ITMI20022511A1 (en) * 2002-11-26 2004-05-27 Victorix Assets Ltd USE OF PHARMACEUTICAL COMPOSITIONS CONTAINING ETHYL ESTERS OF OMEGA-3 POLYUNSATURATED ACIDS IN THE ORDER OF ATRIAL FIBRILLATION.
GB0403247D0 (en) 2004-02-13 2004-03-17 Tillotts Pharma Ag A pharmaceutical composition
ES2277557B1 (en) 2005-12-21 2008-07-01 Proyecto Empresarial Brudy, S.L. USE OF DOCOSAHEXAENOIC ACID FOR THE TREATMENT OF OXIDATIVE CELL DAMAGE.
JP2009523414A (en) 2005-12-21 2009-06-25 ブルーディ、テクノロジー、ソシエダッド、リミターダ Use of DHA, EPA or DHA-derived EPA to treat lesions associated with oxidative damage of cells
WO2010028067A1 (en) 2008-09-02 2010-03-11 Amarin Corporation Plc Pharmaceutical composition comprising eicosapentaenoic acid and nicotinic acid and methods of using same
ES2426132T3 (en) 2009-02-10 2013-10-21 Amarin Pharmaceuticals Ireland Limited Use of eicosapentaenoic acid ethyl ester to treat hypertriglyceridemia
NZ595204A (en) * 2009-03-09 2014-11-28 Pronova Biopharma Norge As Compositions comprising a fatty acid oil mixture and a surfactant, and methods and uses thereof
LT2424356T (en) 2009-04-29 2017-11-27 Amarin Pharmaceuticals Ireland Limited Stable pharmaceutical composition and methods of using same
MY198422A (en) 2009-04-29 2023-08-29 Amarin Pharmaceuticals Ie Ltd Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
NZ597193A (en) 2009-06-15 2014-01-31 Amarin Pharmaceuticals Ie Ltd Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy
US20110071176A1 (en) 2009-09-23 2011-03-24 Amarin Pharma, Inc. Pharmaceutical composition comprising omega-3 fatty acid and hydroxy-derivative of a statin and methods of using same
WO2012074930A2 (en) 2010-11-29 2012-06-07 Amarin Pharma, Inc. Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
US11712429B2 (en) 2010-11-29 2023-08-01 Amarin Pharmaceuticals Ireland Limited Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
CA2826663A1 (en) 2011-02-07 2012-08-16 Mochida Pharmaceutical Co., Ltd. Therapeutic agent for diastolic congestive heart failure
US11291643B2 (en) 2011-11-07 2022-04-05 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
EP2775837A4 (en) 2011-11-07 2015-10-28 Amarin Pharmaceuticals Ie Ltd Methods of treating hypertriglyceridemia
JP6307442B2 (en) 2012-01-06 2018-04-04 アマリン ファーマシューティカルス アイルランド リミテッド Compositions and methods for reducing the level of high sensitivity (HS-CRP) in a subject
MX2020013933A (en) 2012-06-29 2022-11-23 Amarin Pharmaceuticals Ie Ltd Methods of reducing the risk of a cardiovascular event in a subject on statin therapy.
US20150265566A1 (en) 2012-11-06 2015-09-24 Amarin Pharmaceuticals Ireland Limited Compositions and Methods for Lowering Triglycerides without Raising LDL-C Levels in a Subject on Concomitant Statin Therapy
US20140187633A1 (en) 2012-12-31 2014-07-03 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis
US9814733B2 (en) 2012-12-31 2017-11-14 A,arin Pharmaceuticals Ireland Limited Compositions comprising EPA and obeticholic acid and methods of use thereof
US9452151B2 (en) 2013-02-06 2016-09-27 Amarin Pharmaceuticals Ireland Limited Methods of reducing apolipoprotein C-III
US9624492B2 (en) 2013-02-13 2017-04-18 Amarin Pharmaceuticals Ireland Limited Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof
US9662307B2 (en) 2013-02-19 2017-05-30 The Regents Of The University Of Colorado Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof
US9283201B2 (en) 2013-03-14 2016-03-15 Amarin Pharmaceuticals Ireland Limited Compositions and methods for treating or preventing obesity in a subject in need thereof
US20140271841A1 (en) 2013-03-15 2014-09-18 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin
US10966968B2 (en) 2013-06-06 2021-04-06 Amarin Pharmaceuticals Ireland Limited Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof
US20150065572A1 (en) 2013-09-04 2015-03-05 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing prostate cancer
US9585859B2 (en) 2013-10-10 2017-03-07 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
US10561631B2 (en) 2014-06-11 2020-02-18 Amarin Pharmaceuticals Ireland Limited Methods of reducing RLP-C
US10172818B2 (en) 2014-06-16 2019-01-08 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
US10406130B2 (en) 2016-03-15 2019-09-10 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
WO2018213663A1 (en) 2017-05-19 2018-11-22 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject having reduced kidney function
US11058661B2 (en) 2018-03-02 2021-07-13 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L
TN2021000013A1 (en) 2018-09-24 2022-10-03 Amarin Pharmaceuticals Ie Ltd Methods of reducing the risk of cardiovascular events in a subject
KR20240012390A (en) 2021-04-21 2024-01-29 애머린 파마슈티칼스 아일랜드 리미티드 How to Reduce Your Risk of Heart Failure

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1308613B1 (en) * 1999-02-17 2002-01-09 Pharmacia & Upjohn Spa ESSENTIAL FATTY ACIDS IN THE PREVENTION OF CARDIOVASCULAR EVENTS.
EP1157692B1 (en) * 2000-05-22 2005-10-05 Pro Aparts - Investimentos E Consultoria Lda Composition of fatty acids containing at least 80% by weight of EPA and DHA or their derivatives and its pharmaceutical use
ITMI20010129A1 (en) * 2001-01-25 2002-07-25 Pharmacia & Upjohn Spa ESSENTIAL FATTY ACIDS IN THE THERAPY OF HEART INSUFFICIENCY AND HEART FAILURE

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
None *
See also references of WO03068216A1 *

Also Published As

Publication number Publication date
WO2003068216A1 (en) 2003-08-21
AU2003210210A1 (en) 2003-09-04
ITMI20020269A0 (en) 2002-02-12
ITMI20020269A1 (en) 2003-08-12

Similar Documents

Publication Publication Date Title
EP1474125A1 (en) The use of omega-3 polyunsaturated acids ethyl esters in patients suffering from heart failure
JP5441287B2 (en) Essential fatty acids to prevent cardiovascular events
EP1310249B1 (en) Use of polyunsatured fatty acids for the primary prevention of major cardiovascular events
MX2013011295A (en) Compositions for the treatment of neurologic disorders.
US8592439B2 (en) Long-term treatment of symptomatic heart failure
US6358997B1 (en) Tocopherol and tocotrienol compositions
RU2387448C2 (en) Essential fatty acids for prevention and/or treatment of depression in patients suffering from coronary heart disease or coronary artery disease
US6207187B1 (en) Compositions based on tocopherols
JP2020503388A (en) Omega-3 fatty acid composition for preventing and / or treating cachexia
JP2007532605A5 (en)
WO1996019218A1 (en) Tocopherol and tocotrienol compositions
MXPA01008213A (en) Essential fatty acids in the prevention of cardiovascular events

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20040728

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO

17Q First examination report despatched

Effective date: 20070307

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20070918